Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label pharmacokinetics and metabolism study of BI 1358894 in healthy male volunteers
NL-OMON49751Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bi 1358894 in major depressive disorder (MDD) and borderline personality disorder (BPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Mass balance recoveries of total radioactivity in urine and faeces and Amount of radioactivity excreted as percentage of dose. Started Oct 2020; status: active, not recruiting.
02
Drugs
bi 1358894
03
Conditions
major depressive disorder (MDD)borderline personality disorder (BPD)
Beyond the preview
Go deeper on NL-OMON49751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49751.